Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
Balance Sheet
Inspect the capital base behind the business.
Assets
$70.07M
FY 2025 · Annual
+55.9% YoYLiabilities
$35.02M
FY 2025 · Annual
-31.1% YoYEquity
$35.05M
FY 2025 · Annual
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.1M | 23.77M | 13.27M | 26.63M | 36.72M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 1.55M | 8.81M | 12.88M | 23.18M |
| Inventory | 0 | 576K | 2.16M | 1.06M | 1.56M |
| Other Current Assets | 253K | 63K | 44K | 466K | 1.37M |
| Total Current Assets | 22.39M | 26.73M | 26.86M | 44.12M | 66.56M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.79M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 27K | 211K | 6K | 822K | 710.62K |
| Total Non-current Assets | 27K | 211K | 6K | 822K | 3.5M |
| Total Assets | 22.41M | 26.94M | 26.86M | 44.95M | 70.07M |
| Account Payables | 777K | 2.39M | 3.78M | 3.24M | 4.63M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 247.55K |
| Other Current Liabilities | 0 | 0 | 0 | 248K | (10.25K) |
| Total Current Liabilities | 1.65M | 4.61M | 7.55M | 6.92M | 10.5M |
| Long-term Debt | 4.99M | 24.9M | 30.93M | 19.34M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 24.56M |
| Other Non-current Liabilities | 0 | 0 | 0 | 24.56M | 0 |
| Total Non-current Liabilities | 4.99M | 24.9M | 30.93M | 43.9M | 24.52M |
| Total Liabilities | 6.64M | 29.51M | 38.49M | 50.82M | 35.02M |
| Common Stock | 140.8M | 142.59M | 144.31M | 145.61M | 189.56M |
| Retained Earnings | (179.49M) | (203.2M) | (219.25M) | (219.68M) | (229.36M) |
| Accumulated OCI | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Other Stockholders Equity | 0 | 25.75K | 0 | 1 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.77M | (2.57M) | (11.62M) | (5.87M) | 35.05M |
| Total Debt | 4.99M | 24.9M | 30.95M | 19.34M | 0 |
| Net Debt | (16.11M) | 1.13M | 17.69M | (7.29M) | (36.72M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $40.2M |
| Receivables | $18.8M |
| Inventory | $1.9M |
| Other Current | $6.1M |
| Total Current Assets | $66.9M |
| Long-term Investments | $4.3M |
| Other Non-current | $691.0K |
| Total Non-current Assets | $4.9M |
| Total Assets | $71.8M |
Analysis
Selected assets total $71.8M for Latest. The largest visible component is Cash & Equivalents at $40.2M, about 55.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Market cap
$548.02M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Market cap
$448.71M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Market cap
$435.76M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Market cap
$320.09M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Market cap
$295.50M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Market cap
$275.32M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Market cap
$193.69M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Market cap
$84.48M
Caribou Biosciences, Inc.
NASDAQ:CRBU
Market cap
$39.10M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Market cap
$29.11M
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
How much cash does FENC have?
Fennec Pharmaceuticals Inc. (FENC) reported $36.72M in cash and equivalents in fiscal 2025.
How much debt does FENC carry?
Fennec Pharmaceuticals Inc. (FENC) reported $0.00 of total debt, with net debt of -$36.72M.
Continue the stock analysis
Jump to another research area for this company.